<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36283919</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1995-9133</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi</Title><ISOAbbreviation>J Microbiol Immunol Infect</ISOAbbreviation></Journal><ArticleTitle>Long COVID: An inevitable sequela of SARS-CoV-2 infection.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>9</EndPage><MedlinePgn>1-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jmii.2022.10.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1684-1182(22)00186-4</ELocationID><Abstract><AbstractText>At present, there are more than 560 million confirmed cases of the coronavirus disease 2019 (COVID-19) worldwide. Although more than 98% of patients with severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection can survive acute COVID, a significant portion of survivors can develop residual health problems, which is termed as long COVID. Although severe COVID-19 is generally associated with a high risk of long COVID, patients with asymptomatic or mild disease can also show long COVID. The definition of long COVID is inconsistent and its clinical manifestations are protean. In addition to general symptoms, such as fatigue, long COVID can affect many organ systems, including the respiratory, neurological, psychosocial, cardiovascular, gastrointestinal, and metabolic systems. Moreover, patients with long COVID may experience exercise intolerance and impaired daily function and quality of life. Long COVID may be caused by SARS-CoV-2 direct injury or its associated immune/inflammatory response. Assessment of patients with long COVID requires comprehensive evaluation, including history taking, physical examination, laboratory tests, radiography, and functional tests. However, there is no known effective treatment for long COVID. Based on the limited evidence, vaccines may help to prevent the development of long COVID. As long COVID is a new clinical entity that is constantly evolving, there are still many unknowns, and further investigation is warranted to enhance our understanding of this disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Chih-Cheng</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Division of Hospital Medicine, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Chi-Kuei</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, E-Da Hospital, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yen</LastName><ForeName>Muh-Yong</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Cheng Hsin General Hospital, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ping-Ing</ForeName><Initials>PI</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Wen-Chien</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsueh</LastName><ForeName>Po-Ren</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, China Medical University Hospital, Taichung, Taiwan; Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan; School of Medicine, China Medical University, Taichung, Taiwan; Departments of Laboratory Medicine and Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: hsporen@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Microbiol Immunol Infect</MedlineTA><NlmUniqueID>100956211</NlmUniqueID><ISSNLinking>1684-1182</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Post-acute COVID</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>25</Day><Hour>22</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36283919</ArticleId><ArticleId IdType="pmc">PMC9576029</ArticleId><ArticleId IdType="doi">10.1016/j.jmii.2022.10.003</ArticleId><ArticleId IdType="pii">S1684-1182(22)00186-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization  https://covid19.who.int/</Citation></Reference><Reference><Citation>Lai C.C., Liu Y.H., Wang C.Y., Wang Y.H., Hsueh S.C., Yen M.Y., et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. J Microbiol Immunol Infect. 2020;53:404&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7128959</ArticleId><ArticleId IdType="pubmed">32173241</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao W., Zhang W., Fang X., Yu D., Wang X. Challenges of SARS-CoV-2 omicron variant and appropriate countermeasures. J Microbiol Immunol Infect. 2022;55:387&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9040366</ArticleId><ArticleId IdType="pubmed">35501267</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng M.Y., Hsih W.H., Ho M.W., Lai Y.C., Liao W.C., Chen C.Y., et al. Younger adults with mild-to-moderate COVID-19 exhibited more prevalent olfactory dysfunction in Taiwan. J Microbiol Immunol Infect. 2021;54:794&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7869675</ArticleId><ArticleId IdType="pubmed">33610511</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin K.Y., Wu P.Y., Liu W.D., Sun H.Y., Hsieh S.M., Sheng W.H., et al. Effectiveness of COVID-19 vaccination among people living with HIV during a COVID-19 outbreak. J Microbiol Immunol Infect. 2022;55:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9069984</ArticleId><ArticleId IdType="pubmed">35577735</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai C.C., Chao C.M., Hsueh P.R. Clinical efficacy of antiviral agents against coronavirus disease 2019: a systematic review of randomized controlled trials. J Microbiol Immunol Infect. 2021;54:767&#x2013;775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233451</ArticleId><ArticleId IdType="pubmed">34253490</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai C.C., Chen I.T., Chao C.M., Lee P.I., Ko W.C., Hsueh P.R. COVID-19 vaccines: concerns beyond protective efficacy and safety. Expert Rev Vaccines. 2021;20:1013&#x2013;1025.</Citation><ArticleIdList><ArticleId IdType="pubmed">34180347</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention  https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html</Citation></Reference><Reference><Citation>Greenhalgh T., Knight M., A'Court C., Buxton M., Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026.</Citation><ArticleIdList><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivan M., Taylor S. NICE guideline on long covid. BMJ. 2020;371:m4938.</Citation><ArticleIdList><ArticleId IdType="pubmed">33361141</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22:e102&#x2013;e107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Haupert S.R., Zimmermann L., Shi X., Fritsche L.G., Mukherjee B. Global prevalence of post COVID-19 condition or long COVID: a meta-analysis and systematic review. J Infect Dis. 2022:jiac136. doi: 10.1093/infdis/jiac136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D., Sun A., Ssentongo A.E., Ba D.M., Parsons N., Poudel G.R., et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. 2021;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C., Palacios-Ce&#xf1;a D., G&#xf3;mez-Mayordomo V., Florencio L.L., Cuadrado M.L., Plaza-Manzano G., et al. Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: a systematic review and meta-analysis. Eur J Intern Med. 2021;92:55&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8206636</ArticleId><ArticleId IdType="pubmed">34167876</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y., Deng J., Liu Q., Du M., Liu M., Liu J. Long-term consequences of COVID-19 at 6 months and above: a systematic review and meta-analysis. Int J Environ Res Publ Health. 2022;19:6865.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9180091</ArticleId><ArticleId IdType="pubmed">35682448</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S., Wegman-Ostrosky T., Ayuzo Del Valle N.C., Perelman C., Sepulveda R., Rebolledo P.A., et al. Long-COVID in children and adolescents: a systematic review and meta-analyses. Sci Rep. 2022;12:9950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9226045</ArticleId><ArticleId IdType="pubmed">35739136</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini E., Levi R., Sarti R., Pozzi C., Mollura M., Mantovani A., et al. Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers. JAMA. 2022 doi: 10.1001/jama.2022.11691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.11691</ArticleId><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Bowe B., Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022;28:1461&#x2013;1467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Wang F., Shen Y., Zhang X., Cen Y., Wang B., et al. Symptoms and health outcomes among survivors of COVID-19 infection 1 year after discharge from hospitals in Wuhan, China. JAMA Netw Open. 2021;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8482055</ArticleId><ArticleId IdType="pubmed">34586367</ArticleId></ArticleIdList></Reference><Reference><Citation>Morin L., Savale L., Pham T., Colle R., Figueiredo S., Harrois A., et al. Four-month clinical status of a cohort of patients after hospitalization for COVID-19. JAMA. 2021;325:1525&#x2013;1534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7970386</ArticleId><ArticleId IdType="pubmed">33729425</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik P., Patel K., Pinto C., Jaiswal R., Tirupathi R., Pillai S., et al. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)-A systematic review and meta-analysis. J Med Virol. 2022;94:253&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8662132</ArticleId><ArticleId IdType="pubmed">34463956</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Q., Zheng B., Daines L., Sheikh A. Long-term sequelae of COVID-19: a systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms. Pathogens. 2022;11:269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8875269</ArticleId><ArticleId IdType="pubmed">35215212</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T., Yan M.Z., Li X., Lau E.H.Y. Sequelae of COVID-19 among previously hospitalized patients up to 1 year after discharge: a systematic review and meta-analysis. Infection. 2022:1&#x2013;43. doi: 10.1007/s15010-022-01862-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-022-01862-3</ArticleId><ArticleId IdType="pmc">PMC9244338</ArticleId><ArticleId IdType="pubmed">35750943</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Q., Xu M., Li J., Liu Y., Zhang J., Xu Y., et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect. 2021;27:89&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7510771</ArticleId><ArticleId IdType="pubmed">32979574</ArticleId></ArticleIdList></Reference><Reference><Citation>Daugherty S.E., Guo Y., Heath K., Dasmari&#xf1;as M.C., Jubilo K.G., Samranvedhya J., et al. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2021;373:n1098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8132065</ArticleId><ArticleId IdType="pubmed">34011492</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise J. Long covid-19: hair loss and sexual dysfunction are among wilder symptoms, study finds. BMJ. 2022;27:378. doi: 10.1136/bmj.o1887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.o1887</ArticleId><ArticleId IdType="pubmed">35896202</ArticleId></ArticleIdList></Reference><Reference><Citation>Go&#xeb;rtz Y.M.J., Van Herck M., Delbressine J.M., Vaes A.W., Meys R., Machado F.V.C., et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020;6(4):542. doi: 10.1183/23120541.00542-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00542-2020</ArticleId><ArticleId IdType="pmc">PMC7491255</ArticleId><ArticleId IdType="pubmed">33257910</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpin S.J., McIvor C., Whyatt G., Adams A., Harvey O., McLean L., et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med Virol. 2021;93:1013&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pubmed">32729939</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal S., Barnett J., Brill S.E., Brown J.S., Denneny E.K., Hare S.S., et al. 'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2021;76:396&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7615158</ArticleId><ArticleId IdType="pubmed">33172844</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold D.T., Hamilton F.W., Milne A., Morley A.J., Viner J., Attwood M., et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. 2021;76:399&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7716340</ArticleId><ArticleId IdType="pubmed">33273026</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.Y., Adejumo P., See C., Onuma O.K., Miller E.J., Spatz E.S. Characteristics of patients referred to a cardiovascular disease clinic for post-acute sequelae of SARS-CoV-2 infection. Am Heart J. 2022;18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9277988</ArticleId><ArticleId IdType="pubmed">35856065</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinzon R.T., Wijaya V.O., Jody A.A., Nunsio P.N., Buana R.B. Persistent neurological manifestations in long COVID-19 syndrome: a systematic review and meta-analysis. J Infect Public Health. 2022;15:856&#x2013;869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9221935</ArticleId><ArticleId IdType="pubmed">35785594</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D., Khunti K., Nafilyan V., Maddox T., Humberstone B., Diamond I., et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ. 2021;372:n693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8010267</ArticleId><ArticleId IdType="pubmed">33789877</ArticleId></ArticleIdList></Reference><Reference><Citation>Ormiston C.K., &#x15a;wi&#x105;tkiewicz I., Taub P.R. Postural orthostatic tachycardia syndrome as a sequela of COVID-19. Heart Rhythm. 2022;S1547&#x2013;5271(22):2185&#x2013;2193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9287587</ArticleId><ArticleId IdType="pubmed">35853576</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezel-Potts E., Douiri A., Sun X., Chowienczyk P.J., Shah A.M., Gulliford M.C. Cardiometabolic outcomes up to 12 months after COVID-19 infection. A matched cohort study in the UK. PLoS Med. 2022;19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9295991</ArticleId><ArticleId IdType="pubmed">35853019</ArticleId></ArticleIdList></Reference><Reference><Citation>Burekovic A., Asimi Z.V., Divanovic A., Halilovic D. Diabetes - a consequence of COVID-19 infection. Mater Sociomed. 2022;34:4&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9229352</ArticleId><ArticleId IdType="pubmed">35801074</ArticleId></ArticleIdList></Reference><Reference><Citation>Jedrzejak A.P., Urbaniak E.K., Wasko J.A., Ziojla N., Borowiak M. Diabetes and SARS-CoV-2-is there a mutual connection? Front Cell Dev Biol. 2022;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9234398</ArticleId><ArticleId IdType="pubmed">35769263</ArticleId></ArticleIdList></Reference><Reference><Citation>Khunti K., Del Prato S., Mathieu C., Kahn S.E., Gabbay R.A., Buse J.B. COVID-19, Hyperglycemia, and new-onset diabetes. Diabetes Care. 2021;44:2645&#x2013;2655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8669536</ArticleId><ArticleId IdType="pubmed">34625431</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee M., Pal R., Dutta S. Risk of incident diabetes post-COVID-19: a systematic review and meta-analysis. Prim Care Diabetes. 2022;S1751-S9918(22) doi: 10.1016/j.pcd.2022.05.009. 0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pcd.2022.05.009</ArticleId><ArticleId IdType="pmc">PMC9148988</ArticleId><ArticleId IdType="pubmed">35654679</ArticleId></ArticleIdList></Reference><Reference><Citation>Birabaharan M., Kaelber D.C., Pettus J.H., Smith D.M. Risk of new-onset type 2 diabetes in 600 055 people after COVID-19: a cohort study. Diabetes Obes Metabol. 2022;24:1176&#x2013;1179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9035030</ArticleId><ArticleId IdType="pubmed">35112782</ArticleId></ArticleIdList></Reference><Reference><Citation>Queiroz M.A.F., Neves P., Lima S.S., Lopes J.D.C., Torres M., Vallinoto I., et al. Cytokine profiles associated with acute COVID-19 and long COVID-19 syndrome. Front Cell Infect Microbiol. 2022;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9279918</ArticleId><ArticleId IdType="pubmed">35846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Wais T., Hasan M., Rai V., Agrawal D.K. Gut-brain communication in COVID-19: molecular mechanisms, mediators, biomarkers, and therapeutics. Expet Rev Clin Immunol. 2022 doi: 10.1080/1744666X.2022.2105697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2022.2105697</ArticleId><ArticleId IdType="pmc">PMC9388545</ArticleId><ArticleId IdType="pubmed">35868344</ArticleId></ArticleIdList></Reference><Reference><Citation>Vianello A., Guarnieri G., Braccioni F., Lococo S., Molena B., Cecchetto A., et al. The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors. Clin Chem Lab Med. 2022;60:307&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pubmed">34783228</ArticleId></ArticleIdList></Reference><Reference><Citation>Durstenfeld M.S., Peluso M.J., Kaveti P., Hill C., Li D., Sander E., et al. Inflammation during early post-acute COVID-19 is associated with reduced exercise capacity and Long COVID symptoms after 1 year. medRxiv. 2022 doi: 10.1101/2022.05.17.22275235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.05.17.22275235</ArticleId></ArticleIdList></Reference><Reference><Citation>Gy&#xf6;ngy&#xf6;si M., Alcaide P., Asselbergs F.W., Brundel B., Camici G.G., da Costa Martins P., et al. Long COVID and the cardiovascular system - elucidating causes and cellular mechanisms in order to develop targeted diagnostic and therapeutic strategies: a joint Scientific Statement of the ESC Working Groups on Cellular Biology of the Heart and Myocardial &amp; Pericardial Diseases. Cardiovasc Res. 2022 doi: 10.1093/cvr/cvac115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvac115</ArticleId><ArticleId IdType="pmc">PMC9384470</ArticleId><ArticleId IdType="pubmed">35875883</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah A.S., Wong A.W., Hague C.J., Murphy D.T., Johnston J.C., Ryerson C.J., et al. A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations. Thorax. 2021;76:402&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">33273023</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall J., Myall K., Lam J.L., Mason T., Mukherjee B., West A., et al. Identifying patients at risk of post-discharge complications related to COVID-19 infection. Thorax. 2021;76:408&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">33542090</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellan M., Soddu D., Balbo P.E., Baricich A., Zeppegno P., Avanzi G.C., et al. Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge. JAMA Netw Open. 2021;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7841464</ArticleId><ArticleId IdType="pubmed">33502487</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X., Liu X., Zhou Y., Yu H., Li R., Zhan Q., et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021;9:747&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8099316</ArticleId><ArticleId IdType="pubmed">33964245</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhi H., Ji X., Zhao Z., Liang H., Zhong S., Luo Y., et al. Risk factors for impaired pulmonary diffusion function in convalescent COVID-19 patients: a systematic review and meta-analysis. EClinicalMedicine. 2022;49</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9137275</ArticleId><ArticleId IdType="pubmed">35663303</ArticleId></ArticleIdList></Reference><Reference><Citation>Skj&#xf8;rten I., Ankerstjerne O.A.W., Trebinjac D., Br&#xf8;nstad E., Rasch-Halvorsen &#xd8;., Einvik G., et al. Cardiopulmonary exercise capacity and limitations 3 months after COVID-19 hospitalisation. Eur Respir J. 2021;58</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8247555</ArticleId><ArticleId IdType="pubmed">34210791</ArticleId></ArticleIdList></Reference><Reference><Citation>Newell K.L., Waickman A.T. Inflammation, immunity, and antigen persistence in post-acute sequelae of SARS-CoV-2 infection immunity and inflammation in post-acute sequelae of SARS-CoV-2 infection. Curr Opin Immunol. 2022;77 doi: 10.1016/j.coi.2022.102228. 2022;23:194-202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2022.102228</ArticleId><ArticleId IdType="pmc">PMC9127180</ArticleId><ArticleId IdType="pubmed">35724449</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Yu C., Jing H., Wu X., Novakovic V.A., Xie R., et al. Long COVID: the nature of thrombotic sequelae determines the necessity of early anticoagulation. Front Cell Infect Microbiol. 2022;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9016198</ArticleId><ArticleId IdType="pubmed">35449732</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Shao M., Zeng X., Qian P., Huang H. Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy. Signal Transduct Targeted Ther. 2021;6:367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8526712</ArticleId><ArticleId IdType="pubmed">34667157</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes E., Wist J., Masuda R., Lodge S., Nitschke P., Kimhofer T., et al. Incomplete systemic recovery and metabolic phenoreversion in post-acute-phase nonhospitalized COVID-19 patients: implications for assessment of post-acute COVID-19 syndrome. J Proteome Res. 2021;20:3315&#x2013;3329.</Citation><ArticleIdList><ArticleId IdType="pubmed">34009992</ArticleId></ArticleIdList></Reference><Reference><Citation>Creech C.B., Anderson E., Berthaud V., Yildirim I., Atz A.M., Melendez Baez I., et al. Evaluation of mRNA-1273 covid-19 vaccine in children 6 to 11 years of age. N Engl J Med. 2022;386:2011&#x2013;2023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9127699</ArticleId><ArticleId IdType="pubmed">35544369</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunkle L.M., Kotloff K.L., Gay C.L., &#xc1;&#xf1;ez G., Adelglass J.M., Barrat Hern&#xe1;ndez A.Q., et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N Engl J Med. 2022;386:531&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8693692</ArticleId><ArticleId IdType="pubmed">34910859</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin M.J., Ustianowski A., De Wit S., Launay O., Avila M., Templeton A., et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of covid-19. N Engl J Med. 2022;386:2188&#x2013;2200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9069994</ArticleId><ArticleId IdType="pubmed">35443106</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreira E.D., Jr., Kitchin N., Xu X., Dychter S.S., Lockhart S., Gurtman A., et al. Safety and efficacy of a third Dose of BNT162b2 Covid-19 vaccine. N Engl J Med. 2022;386:1910&#x2013;1921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006787</ArticleId><ArticleId IdType="pubmed">35320659</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J., Gray G., Vandebosch A., C&#xe1;rdenas V., Shukarev G., Grinsztejn B., et al. Final analysis of efficacy and safety of single-dose Ad26.COV2.S. N Engl J Med. 2022;386:847&#x2013;860.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8849184</ArticleId><ArticleId IdType="pubmed">35139271</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Kaabi N., Zhang Y., Xia S., Yang Y., Al Qahtani M.M., Abdulrazzaq N., et al. Effect of 2 Inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326:35&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8156175</ArticleId><ArticleId IdType="pubmed">34037666</ArticleId></ArticleIdList></Reference><Reference><Citation>Reindl-Schwaighofer R., Heinzel A., Mayrdorfer M., Jabbour R., Hofbauer T.M., Merrelaar A., et al. Comparison of SARS-CoV-2 antibody response 4 weeks after homologous vs heterologous third vaccine dose in kidney transplant recipients: a randomized clinical trial. JAMA Intern Med. 2022;182:165&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8689434</ArticleId><ArticleId IdType="pubmed">34928302</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephenson K.E., Le Gars M., Sadoff J., de Groot A.M., Heerwegh D., Truyers C., et al. Immunogenicity of the Ad26.COV2.S vaccine for COVID-19. JAMA. 2021;325:1535&#x2013;1544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7953339</ArticleId><ArticleId IdType="pubmed">33704352</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia S., Duan K., Zhang Y., Zhao D., Zhang H., Xie Z., et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324:951&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7426884</ArticleId><ArticleId IdType="pubmed">32789505</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M., Penfold R.S., Merino J., Sudre C.H., Molteni E., Berry S., et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22:43&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown D.A., O'Brien K.K. Conceptualising Long COVID as an episodic health condition. BMJ Glob Health. 2021;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8460526</ArticleId><ArticleId IdType="pubmed">34551971</ArticleId></ArticleIdList></Reference><Reference><Citation>Nurek M., Rayner C., Freyer A., Taylor S., J&#xe4;rte L., MacDermott N., et al. Recommendations for the recognition, diagnosis, and management of long COVID: a Delphi study. Br J Gen Pract. 2021;71:e815&#x2013;e825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8510689</ArticleId><ArticleId IdType="pubmed">34607799</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H., Raza S., Nowell J., Young M., Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374:n1648.</Citation><ArticleIdList><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Zilberman-Itskovich S., Catalogna M., Sasson E., Elman-Shina K., Hadanny A., Lang E., et al. Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial. Sci Rep. 2022;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9276805</ArticleId><ArticleId IdType="pubmed">35821512</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Anglin K., Durstenfeld M.S., Martin J.N., Kelly J.D., Hsue P.Y., et al. Effect of oral nirmatrelvir on long COVID symptoms: 4 cases and rationale for systematic studies. Pathog Immun. 2022;7:95&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9254867</ArticleId><ArticleId IdType="pubmed">35800257</ArticleId></ArticleIdList></Reference><Reference><Citation>Ota S., Sugawa S., Suematsu E., Shinoda M., Izumizaki M., Shinkai M. Possibility of underestimation of COVID-19 prevalence by PCR and serological tests. J Microbiol Immunol Infect. 2021;S1684&#x2013;1182(21):192&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8479325</ArticleId><ArticleId IdType="pubmed">34642099</ArticleId></ArticleIdList></Reference><Reference><Citation>Shastri J., Yadav P.D., Agrawal S., Shete A.M., Nyayanit D.A., Parikh S., et al. Community transmission of SARS-CoV-2 with B.1.1.7 lineage in Mumbai, India. J Microbiol Immunol Infect. 2021;S1684&#x2013;1182(21) doi: 10.1016/j.jmii.2021.10.004. 00232-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2021.10.004</ArticleId><ArticleId IdType="pmc">PMC8563497</ArticleId><ArticleId IdType="pubmed">34772636</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong N.S., Chung S.L., Lee S.S. The challenges of enhancing global preparedness in response to the impending Omicron pandemic. J Microbiol Immunol Infect. 2022;55:549&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8935661</ArticleId><ArticleId IdType="pubmed">35331664</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao C.M., Lai C.C., Yu W.L. COVID-19 associated mucormycosis - an emerging threat. J Microbiol Immunol Infect. 2022;55:183&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8755409</ArticleId><ArticleId IdType="pubmed">35074291</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang K.M., Epstein M.E., Kennedy W.A., 3rd, Niknam N. Supraglottitis as the sole manifestation of COVID-19 in a patient who received two doses of mRNA vaccine. J Microbiol Immunol Infect. 2022;S1684&#x2013;1182(22) 00064-0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9046100</ArticleId><ArticleId IdType="pubmed">35545499</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim J.Y., Wu P.S., Cheng C.F., Yiang G.T., Yu C.H. Characteristics, contacts, and relative risk of SARS-CoV-2 infection among children during school closures. J Microbiol Immunol Infect. 2021;S1684&#x2013;1182(21):274&#x2013;277. doi: 10.1016/j.jmii.2021.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2021.12.004</ArticleId><ArticleId IdType="pmc">PMC8719363</ArticleId><ArticleId IdType="pubmed">35016846</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao T.S., Zeng H.L., Zhang X., Chen X., Jiang W.L., Du J., et al. Neurological manifestations in COVID-19 patients and their application in predicting fatal disease: a retrospective cohort study. J Microbiol Immunol Infect. 2022;55:445&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8384758</ArticleId><ArticleId IdType="pubmed">34503922</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardoso Dos Santos K., Rosa da Costa E Silva G., Alves Moura W., Magalh&#xe3;es L.S., Rodrigues de Oliveira B., Dos Santos Carvalho P.M.R., et al. SARS-CoV-2 infection in vulnerable population in Goiania, Central Brazil. J Microbiol Immunol Infect. 2022;55:552&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8390405</ArticleId><ArticleId IdType="pubmed">34465555</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T., Liu D., Tian D., Xia L. The roles of nausea and vomiting in COVID-19: did we miss something? J Microbiol Immunol Infect. 2021;54:541&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7568482</ArticleId><ArticleId IdType="pubmed">34435559</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>